This page shows the latest BIIB059 news and features for those working in and with pharma, biotech and healthcare.
Biogen has dosed the first patient in a global phase 2/3 study of litifilimab (also known as BIIB059) in participants with cutaneous lupus erythematosus (CLE), the company announced.
as BIIB059 – an investigational drug developed to treat lupus.
Biogen has started dosing patients in a late-stage study evaluating its potential systemic lupus erythematosus (SLE) treatment BIIB059. ... added. In addition to BIIB059, Biogen also has another investigational lupus asset – dapirolizumab pegol –
The SLE arm only tested the highest 450mg dose of BIIB059, and showed the drug reduced the number of joints with active inflammation compared to placebo at 24 weeks. ... We are excited by the LILAC study results, and the potential for BIIB059 to be a
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
No results were found
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...